Strategic partnerships Adial recently completed a business combination with Azora Therapeutics and appointed new leadership, signaling a strategic expansion and potential for joint BD efforts in CNS and GI indications. Explore co-development or licensing discussions around AT177 and AD04 companion diagnostics to broaden therapeutic applicability.

Clinical pipeline Lead programs include AD04 for Alcohol Use Disorder with genotype-targeted approach and a newly acquired AhR program AT177 for ulcerative colitis. Leverage these programs to position Adial for collaborations in precision medicine, biomarker-enabled trials, and targeted patient recruitment.

Genetics driven Proprietary companion diagnostic tests to identify target genotypes for AD04 present a differentiator. Opportunities exist to partner with diagnostic developers, payers, and CLIA-certified labs to co-create tests that enable genotype-based patient stratification and faster trial enrollment.

Financial readiness Current funding raised and a modest revenue base indicate room for pharma partnerships, joint ventures, or milestone-driven deals. Propose BD angles focused on cost-sharing, upfronts tied to Phase 3 milestones, and later-stage co-development funding.

Engagement signals Recent executive hires, board additions, and active conference presence (Oppenheimer Healthcare Life Sciences Conference) signal a readiness for outreach. Target interactions around strategic collaborations, licensing discussions, and potential acquisitions or in-licensing of adjacent assets to accelerate clinical timelines.